25Apr 2023
Hope for the Critically Ill: Tocilizumab Offers Early Relief from COVID-19 Complications

Hope for the Critically Ill: Tocilizumab Offers Early Relief from COVID-19 Complications

The study aimed to evaluate the effectiveness of early use of Tocilizumab (TCZ) compared to standard of care in preventing severe COVID-19-related multiorgan dysfunction in critically ill patients. The multicenter, retrospective cohort study included 300 patients who were categorized into two groups. Patients who received TCZ had a lower multiorgan dysfunction score on day three of ICU admission, and a statistically significant decrease in respiratory failure requiring mechanical ventilation. The study also found that patients who received TCZ had significantly lower 30-day and in-hospital mortality rates. Therefore, the use of TCZ within 24 hours of ICU admission in critically ill patients with COVID-19 was associated with a significantly lower multiorgan dysfunction score and improved mortality rates.

  • #critical care

Like

Save

Share